1. Home
  2. |Insights
  3. |FDA Announces Availability of Decision Tool and SPL Xforms For MoCRA Facility Registration and Product Listings

FDA Announces Availability of Decision Tool and SPL Xforms For MoCRA Facility Registration and Product Listings

Client Alert | 1 min read | 01.12.24

On January 8, 2024, the U.S. Food and Drug Administration (FDA) announced that SPL Xforms, a Structured Product Labeling authoring tool, is now available as an additional option for completing facility registration and product listings mandated by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). As a result, companies may submit their facility registration(s) and product listing(s) in one of four ways:

    1. FDA Direct;
    2. Electronic Submissions Gateway;
    3. SPL Xforms; and
    4. Paper Submissions via FDA Form 5066 (Facility Registration) and FDA Form 5067 (Product Listing).

Completed paper submissions can be emailed to RLC-PaperSubmissions@fda.hhs.gov or mailed to the following address:

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
Office of Cosmetics and Colors
Registration and Listing of Cosmetic Product Facilities and Products Program
5001 Campus Drive, CPK1, Room 1B-046
College Park, MD 20740-3835.

The FDA indicated that it does not intend to enforce the facility registration and product listing requirements until July 1, 2024. Nevertheless, companies are now able to submit this information and are encouraged to do so in advance of the July 1, 2024 enforcement deadline.

The FDA’s Decision Tool should also be of help to cosmetics companies who are still trying to determine whether to register one or more facility.

Contacts

Insights

Client Alert | 8 min read | 11.16.26

OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure

On November 4, 2026, the Office of the Comptroller of the Currency (OCC) issued Bulletin 2026-54 and a Supervisory Framework on Bank Use of Super Intelligence (the “Framework”), an examiner resource addressing banks’ use of artificial intelligence (AI), particularly generative AI and AI agents that can act on their own. The Framework creates no new legal requirements or supervisory expectations, and the OCC states that banks are not expected to use it to assess their own AI use or risk management. Importantly, it identifies as higher risk several AI uses common for banks that are already governed by binding law, such as moving money, making credit decisions, and communicating with customers. A failure in any of those uses could trigger legal liability. Institutions that rely on AI for these tasks should consider the following: ...